CA1111862A

CA1111862A - Process for preparing cyclohexanecarboxylic acid

Info

Publication number: CA1111862A
Application number: CA301,086A
Authority: CA
Inventors: Kanji Noda; Akira Nakagawa; Hiroyuki Ide; Terumi Hachiya; Akihide Koda; Kenji Yamagata
Original assignee: Hisamitsu Pharmaceutical Co Inc
Current assignee: Hisamitsu Pharmaceutical Co Inc
Priority date: 1977-06-16
Filing date: 1978-04-13
Publication date: 1981-11-03
Also published as: GB1593469A; FR2394514A1; IT7849127A0; AR223317A1; NL7804192A; ES469313A1; ATA311678A; AU519919B2; MX5006E; AR222304A1; ZA782228B; US4228304A; JPS545949A; SE7806433L; AT358006B; CA1125304A; SU704452A3; CH633251A5; AU3500378A; DE2818879A1

Abstract

ABSTRACT OF THE DISCLOSURE

The present invention relates to the process for preparing cyclohexanecarboxylic acid of the following formula (I).
(I) The compount of the formula (I) which is obtained by the process of the present invention is entirely novel one which has never been in any printed publications, possessing a high degree of pharmacological activities such as anti-aller-gic, anti-inflammatory, anti-ulcerative, antibacterial, anti-thrombotic and liver-function-impraving activities. Therefore, this compound is useful as medicines.
Besides, this compound is surface-active and, therefore, useful as additives for toothpaste and shampoo, as surface active agents for detergents, dispersing agents, emulsifying agents and cosmetics, and also as anticarious agents. In indust-rial fields the aforesaid compound is useful as detergents for keeping textiles soft, as additives for lubricating oil, as anti-rust agents, additives for plastics and also as metal-capturing agent, ion-floating agents and emulsifying agents for other industrial purposes.

Description

1~11862 The present invention relates to the process for preparing cyclohexanecarboxylic acid of the following formula (I).
CH 3 COOI~

CH3 (I) The compound of the formula (I) which is obtained by the process of the present invention is entirely novel one which has never been in any printed publications, possessing a high degree of pharmacological activities such as anti-aller-gic, anti-inflammatory, anti-ulcerative, antibacterial, anti-thrombotic and liver-function-improving activities. Therefore, this compound is useful as medicines.
Besides, this compound is surface-active and, therefore, useful as additives for toothpaste and shampoo, as surface active agents for detergents, dispersing agents, emulsifying agents and cosmetics, and also as anticarious agents. In indust-rial fields the aforesaid compound is useful as detergents for keeping textiles soft, as additives for lubricating oil, as anti-rust agents, additives for plastics and also as metal-capturing agent, ion-floating agents and emulsiying agents for other industrial purposes.
The present invention is characterized with the process for preparing cyclohexanecarboxylic acid of the aforesaid formula I by hydrolizing the compounds of the following general 111~862 formula ~ :
CH ~ X

< H

Y (II) wherein X may be a cyano, lower alkoxycarbonyl or carbamoyl.
The process for preparing the compound of this invention is to be described more particularly below.
CH~_,X CH3 COOH
hydrolysis H ~ H
CH3 ~ CH3 Wherein X has the same meanings as defined above.
The process represented in the aforesaid reaction scheme, the reaction can be made in such a way that the compound represented by the general formula ~ is reacted in water solution of 10-30% mineral acids(e. g.
hydrochloric acid and sulfuric acid) or, for the purpose of keeping the uniformity of the reactions, in organic acids such as acetic acid using mineral acids at room temperature or, if necessary, by heating at 10-120 C for 3 to 5 hours. The said reactions can also be made in water solution of alkali(e;g.
sodium hydroxide, potassium hydroxide, sodium carbonate and potassium carbonate) or in hydrous alcohol at room temperature or, if necessary, by heating at 10-120 C for 3 to 20 hours.
The aforesaid acid or alkali are added in equivalent moles to ~ ' ~ 1 ~ 2 in small excess to the compounds represented by the general formula ~. Another conditions may be quite enough as same as common conditions of hydrolysis.
As indicated below, in the compounds (I) exist two stereo-geometrical isomers, namely, cis-isomer (Ia) and trans-isomer (Ib), COOH CH
CH 3 COO~

H ~H

~ cis-isomer(Ia) ~ trans-isomer(Ib) rhich can be separated by taking advantage of the reactivity of their functional groups and the difference of their spatial configuration(e.g. the formation of clathrate compounds consist-ing of urea, thiourea and cyclo-dextrine or the stability in hydrolytic reactions).
The compounds represented general formula (~)which are the starting materials of this invention can be synthesized in the manner described in, for instance, Gunther Ohloff ~nn, 6~6, 100('57).
The compound represented by the formula I which is obt~ined by the process of this invention may be led to the production of inorganic base such as sodium, potassium and calcium, and also organic base such as monoethanolamine, diethanolamine an triethanolamine.
Hitherto, adrenocortical hormone alone has been known as anti-allergic agents, especially those of delayed t:ype. Howcver3 steroid preparations cause serious side-effects if adminis~ercd ",~

continuously for a long period of time and, therefore, the development of non-steroid anti-allergic agents with less side-effects is in demand. The present inventors synthesized cyclo-hexanecarboxylic acid represented by the formula I in search of novel compounds of non-steroid type and found these compounds having outstanding anti-allergic actions with almost no side-effects both in oral and topical administration after various studies on their pharmacological activities. The compound which is obtained by the process of this invention possess such pharma-cological activities as anti-inflammatory, anti-ulcerative, antibacterial and anti-thrombotic activities. Therefore, this compound is useful as medicines from an industrial viewpoint.
The compound also possess a high degree of surface-activating effect and, therefore, can be used as additives for toothpaste and shampoo, as surface active agents for detergents, dispersing agents, emulsifying agents and cosmetics, and also as anticari-ous agents. Especially as detergents among others, they are useful as a new type of detergent to be used on persons with delicate skin or of allergic constitution, thanks to the fact that the detergents thus prepared are less toxic and milder than conventional ones in their effect on skin or mucous membranes despite their strong surface-activities and also are tasteless and odorless. Besides, the other properties, both physical and chemical, peculiar to the compounds of this invention are found ~pplicable to other various fields and, therefore, the present invention has been brought to completion.
The compound which is obtained by the process of the present invention was tested for their acute toxicities, anti-allergic activities and anti-inflammatory activities. I~ is found that ~11186Z

certain of the compound of the present invention has shown a remarkable effects in all of those tests. The testing methods are described in the following, and the results are summarized in Tables I-V.

(1) Acute toxicity Each test compound suspended in 0.5 % tragacanth gum-saline was administered orally, subcu~aneously or intraperitoneally to animals ddY strain mouse and Wistar strain rats. The 50 ~O lethal dose and the 95 ~ confidence limit were calculated by Litchfi,eld-Wilcoxon's method from the death of animals in 3 weeks following administration.
Table I

Test compound animal LDs o~ alues (mg/kg) P . o .s . c . i . p . _ Compoundof this male rat >10000>10000 ~1780-2400) inYention (Ia) 1690 female rat >10000>1000¦(1470-1940) male mouce 5950 >10000l lllo female mouce (5685-7182)~ >loooo ( 998 male dog >5000 female dog >5000 male rabbit >6000 ¦female rabbit >6000

(2) Homologeous passive cutaneous anaphylaxis in rat Each test compound suspended in 0.5 ~ tragacanth gum-dis-tilled water was administered orally to a group of five male Wistar strain rats (body weight 150-200 g). After one hour 0.1 ml of 5 ~ anti-Dinitrophinol conpled Ascaris rat IgE serum-physiological sodium chloride solution was injected intradermally to dorsum of the rat. After 48 hours, 1 ml saline solution dissolved DNP-Ascaris (protein concentration 2 mg/ml) and 0.25 % Evans blue was injected intravenously. The animals were sacrificed by decapitation 30 minutes after the injection. Thereafter the skin of the animals were removed and the amount of the pigment exuded into the inflamed skin was determined. The percent inhi-bitions were calculated by the ratio of the amounts of exuded pigments to the control.
Table ~

~ ~ _ ._ Test compound Dose(mg/kg) Inhibition~) Compound of this 100 28 invention (Ia) Glycyrrhizin 100 22 Prednisolone l 42

(3) Picryl Chloride induced contact dermatitis At first 0.1 ml of 7 ~ picryl chloride-ethanol solution was applied to skin of the depilated abdomens ~area 2.5X15 mm) of ddY-strain male mice (body weight 20-22 g). After one week each 0.02 ml of 1 ~ picryl chloride-olive oil solution was applied ~11862 topically to the ears of the mouse. The ears the selected mice swelled well enough. After three days 0.1 ml of 7 % picryl chloride-ethanol solution was applied again to the depilated abdomens of the mice. After one week, each 0.02 ml of 1~ picryl chloride-olive oil solution per ear were applied topically to the bilateral ears, and at same time, the test compounds were administered orally. Immediately before and 24 hours after the second challenge, the thickness of the ears was measured and the swelling was calculated. The percent inhibitions were calculated by the ratio of the each swelling to the control.

Table ~

~. _ _ Test compound Dose(mg/kg) Inhibition(%) .
Compound of this 100 49 invention (Ia) Compound of this 100 44 invention ~Ib) Prednisolone ~ 5 32 . .

(4) ~lediator release on lung fragment of guinea pig.
A group of Hartley strain male guinea pigs (body weight 250-300 g) were administrated intraperitoneally anti-BP0-BGG IgE
serum. The animals were sacrificed by decapitation, and those sensitized lungs were isolated for use. 500 mg of the fragments of the sensitized lungs were immersed in the 4.5 ml of Tyrode's solution. Thereafter, the immersed solution preincubated for five minutes at 37 C were added to 0.25 ml of test compounds dissolved or suspended Tyrode's solution, and at three minutes thereafter, BP0-BSA at the final concentration of 10- 6 g/ml.
Following 10 minute incubation, the amount of the released hista-mine were determined by bioassay.

Tabl~ ~
~ . .
Test compound concentration(g/ml) Inhibition(%) _ _ Compound of this 10- 4 24.2 invention (Ia) Glycyrrhizin 10- 4 8.0 Prednisolone 10- 4 4.0

(5) Effect on rat adjuvant polyarthritis A group of eight to ten male Sprague Dawley strain rats (body weight 240-280 g) were used. 0.1 ml of Complete Freuind's adjuvant (C~A, Mycobacterium butyricum, 100 mg/10 cc) was injected intradermally to the right hind sole. The animals were given orally the test compound, 200 mg/kg at daily for 21 days after the injection, and the each swelling of the bilateral hind paw was measured at Ibuprofen which was orally administered at a dose of 50 mg/kg/day and Prednisolone which was orally administered at a dose of 0.5 mg/kg/day were administered as reference medicines.

1~11862 Table Y -I
Swelling percent (%) of right hind paw (~reatment of CFA) Test compound day Control ICompound of Ibuprofen Prednisolone this invention(Ia) Q118.1+ 4.3 118.1+ 5.0 118.6+ 5.7 118.4+ 6.0 198.7i 5.1 100.0+ 5.3 98.1+ 6.1 97.3+ 6.5 4279.4+13.5 255.4+13.8 204.7+11.6** 232.7+17.8 7242.1+16.7 216.3+12.8 181.7+14.8* 200.3+22.5 10209.1+15.5 173.8+ 7.1 160.5+12.2* 167.2+19.0 14 j 201.4+17.5 169.5+ 8.0 163.0+11.1 175.0+18.6 17 206.8+18.7 166.0+ 8.6 152.5+11.8* 174.2+18.6 21 210.9il9.3 163.0+10.5* 138.5+12.6** 173.0+23.7 Table V -~
Swelling percent(~) of left hind paw ~non-treatment of CFA) Test compound day Control Compound of Ibuprofen ¦Prednisolone this inv ntion (Ia) 0 -0.4+1.7 -1.3+1.8 -1.7il.3 ~ -1.1+1.0 1 -0.3+1.2 -3.0+1.~ -2.4+1.0 -1.0+1.0 4 -2.3+1.8 -0.8+2.0 -2.3+1.5 1l-1.7+1.1 7 8.4+2.0 4.5+3.3 1.5+1.8* 1 5.7+1.9 10 7.8+3.0 11.8+2.4 7.4+1.8 1 4.5+2.9 1417.2+2.2 13.3+1.6 12.5+1.5 112.5+2.4 1723.4+2.5 13.2+1.7** 8.5+1.5** ~ 9.8+1.4**
2121.3+4.4 8.5+2.0* 8.5+2.0* 7.1+1.5*
_ _ The symbols, * and ** represent the significant difference from control, * at 5 % ; ** at 1 %.

-1~1186Z

Example of the present invention is il]ustrated in the following.
Example A mixture of 120 g of cis and trans-4-isohexyl-1-methyl-cyclohexanecarbonyl-methyl ester (the ratio of cis-isomer and trans-isomer is 7:3) is heated along with 7 g of sodium hydro-xide in S00 ml of hydrous methanol at 50-55 C for 3 hours.
After the reaction, the reaction solvent is distilled off from the mixture under reduced pressure. The residue thus obtained is extracted with ether several times with some iced water added. The aqueous layer is made acid with diluted hydrochloric acid and the crude crystals precipitated are collected by filtration and then washed and dried. The recrys-tallization of these crystals from acetonitrile yields 26 g of trans-4-isohexyl-1-methylcyclohexanecarboxylic acid as color-less prisms, melting at 51-53 C. Furthermore, after ether s distilled ~way the ether layer is added to a solution of 62 g of potassium hydroxide and 700 ml of methanol, and then the mixture is refluxed for 5 hours. After the reaction, the reaction solvent is distilled off from the mixture under reduced pressure. With some iced water added, the residue thus obtained is made acid with hydrochloric acid and the crude crystals precip~tated are collected by filtration and then washed and dried. The recrystallization of these crystals from acetonitrile yielded 70 g of cis-4-isohexyl-1-methylcyclohexanecarboxylic acid as colorless needles, melting at 92-94 C.

Claims

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. The process for preparing cyclohexanecarboxylic acid of the formula I
(I) which comprises hydrolizing the compounds of the following general formula II:
(II) wherein X may be a cyano, lower alkoxycarbonyl or carbamoyl.